Phase II Study of Abarelix Depot for Androgen Independent Prostate Cancer Progression During Gonadotropin-Releasing Hormone Agonist Therapy

Abstract

Treatment of androgen independent prostate cancer with abarelix decreases circulating FSH and maintains anorchid testosterone but does not result in clinical responses.